Ad
Friday, 20 December 2019
Stealth Bio's neuromuscular disorder drug fails trial; shares plummet
Stealth BioTherapeutics Corp's shares crashed on Friday after its lead neuromuscular disorder drug candidate failed to help patients walk better and reduce fatigue, a major setback to the company's wide mitochondrial diseases pipeline.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment